ArticleAmerican journal of clinical and experimental immunology2026
Meta-analysis of the changes in clinical features and characteristics of lung cancer under bronchoscopy.
Article in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to summarize the clinical features and evolutionary changes of lung cancer under bronchoscopy.
methodsRelevant literature on the "clinical characteristics and evolving features of lung cancer observed under bronchoscopy" was retrieved from Chinese and English databases, including CNKI, Wanfang, VIP, PubMed, and Web of Science.
resultsA total of 21 studies published between 2005 and 2023 were included, involving 8,892 patients, with 10 studies in English and 11 in Chinese. All studies were analyzed using a random-effects model with the Freeman-Tukey double arcsine transformation for meta-analysis of single proportions. The pooled estimate for the diagnostic accuracy of bronchoscopy in lung cancer was 2.22 (95% CI: 2.10-2.34; Q=42.21, P<0.01). Regarding pathological types, the pooled estimates were 1.20 for lung squamous cell carcinoma (95% CI: 0.90-1.50; Q=328.08, P<0.01), 0.77 for small cell lung cancer (95% CI: 0.62-0.93; Q=219.43, P<0.01), 0.67 for non-small cell lung cancer (95% CI: 0.49-0.86; Q=66.84, P<0.01), and 1.53 for lung adenocarcinoma (95% CI: 1.06-2.01; Q=2096.93, P<0.01). For age distribution, the pooled estimate was 1.45 for patients aged ≥60 years (95% CI: 0.91-1.99; Q=886.54, P<0.01) and 1.69 for patients aged <60 years (95% CI: 1.15-2.23; Q=886.54, P<0.01). The pooled estimates for male and female patients were 1.59 (95% CI: 1.17-2.02; Q=983.83, P<0.01) and 1.55 (95% CI: 1.12-1.97; Q=983.83, P<0.01), respectively. Regarding bronchoscopic morphological patterns, the pooled estimates were 1.50 for proliferative-type lung cancer (95% CI: 1.25-1.74; Q=180.64, P<0.01), 1.14 for infiltrative-type lung cancer (95% CI: 0.94-1.35; Q=225.58, P<0.01), and 0.83 for lung cancer with non-specific bronchoscopic changes (95% CI: 0.60-1.06; Q=498.02, P<0.01). Meta-regression analysis of lung adenocarcinoma indicated that publication year and study design were significant sources of heterogeneity among the included studies (P<0.01).
conclusionAmong lung cancers diagnosed by bronchoscopy, lung adenocarcinoma was the predominant pathological type, and the proliferative type was the most common bronchoscopic morphological pattern. Most patients were younger than 60 years, and the proportion of male patients was slightly higher than that of female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.